Abstracts Archive - Page 21 of 1683 - ATC Abstracts

2022 American Transplant Congress
Tacrolimus After Rabbit Antithymocyte Globulin And Infliximab Induction Immunosuppression In Kidney Transplantation
O. Viklicky¹, G. Bold², O. Bestard³, P. Hruba¹, I. Zahradka¹, N. M. Otto², M. Stein², A. Sefrin², S. Christakoudi⁴, P. M. Reinke²
¹Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ²Charité, Berlin, Germany, ³Vall d'Hebron, Barcelona, Spain, ⁴King's College, London, United Kingdom
*Purpose: Selective targeting of effector/memory T cells as induction immunosuppression has been discussed in kidney transplantation. Confidence-interval-estimation study may help to estimate range of the…
2022 American Transplant Congress
Ex Vivo End Ischemic Hypothermic Oxygenated Perfusion (hope) Versus Static Cold Storage Prior To Liver Transplantation – Preliminary Results Of The Bridge To Hope Pivotal Multicenter Randomized Controlled Clinical Trial On The Safety And Effectiveness Of The Vitasmart Liver Machine Perfusion System (clinicaltrials.gov: Nct05045794)
D. J. Reich¹, A. Schlegel², M. Rizzari³, D. Foley⁴, M. DeVera⁵, W. Chapman⁶, G. Roll⁷, A. Saharia⁸, C. Quintini⁹, S. Florman¹⁰, S. Merani¹¹, S. Mao¹², A. Pinna¹³, M. Akoad¹⁴, C. Kubal¹⁵, S. Alexopoulos¹⁶, H. Bohorquez¹⁷
¹Drexel University, Philadelphia, PA, ²Careggi U, Florence, Italy, ³Henry Ford, Detroit, MI, ⁴U Wisconsin, Madison, WI, ⁵Loma Linda, Loma Linda, CA, ⁶Washington U, Saint Louis, MO, ⁷UCSF, SF, CA, ⁸Methodist, Houston, TX, ⁹Cleveland Clinic, Cleveland, OH, ¹⁰Mount Sinai, NY, NY, ¹¹U Nebraska, Omaha, NE, ¹²Mayo, Jacksonville, FL, ¹³Cleveland Clinic, Weston, FL, ¹⁴Lahey, Burlington, MA, ¹⁵Indiana U, Indianapolis, IN, ¹⁶Vanderbilt, Nashville, TN, ¹⁷Ochsner, New Orleans, LA
*Purpose: Ex vivo end ischemic hypothermic oxygenated machine perfusion (HOPE) is a simple technique to improve liver transplant (LT) results and the donor shortage. HOPE…
2022 American Transplant Congress
Clusterin Protects Kidney Transplants from Ischemia-Reperfusion Injury by Modulating Neutrophil Infiltration
Y. Shim¹, R. Fan², N. Dvorina², K. McCrae¹, B. William²
¹Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, ²Inflammation and Immunity, Cleveland Clinic Lerner Research Institute, Cleveland, OH
*Purpose: Ischemia-reperfusion injury (IRI) is inevitable during organ transplantation. Clusterin (CLU) has shown to be protective in IRI. Supplementation of storage solution with recombinant CLU…
2022 American Transplant Congress
Longitudinal Mortality Risks and Renal Functional Outcomes in Living Kidney Donors
K. Hotta¹, T. Osawa¹, I. Yokota², T. Inao², T. Tanabe¹, N. Iwahara¹, N. Shinohara¹
¹Urology, Hokkaido University Hospital, Sapporo, Japan, ²Biostatistics, Hokkaido University Graduate School of Medicine, Sapporo, Japan
*Purpose: Previous studies have suggested that living kidney donors do not have a higher risk of death or end-stage kidney disease (ESKD) than the general…
2022 American Transplant Congress
Single Cell RNAseq Analysis of Liver Transplant Rejection Reveals Highly Restricted TCR Clonal Expansion of Tissue-Resident Memory CD8⁺ T Cells That Persist Despite Corticosteroids and ATG Therapy
A. L. Peters¹, G. Begum¹, K. Roskin², E. Woodle³, D. Hildeman⁴
¹Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Department of Bioinformatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Department of Surgery, University of Cincinnati, Cincinnati, OH, ⁴Department of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
*Purpose: Conventional therapy for liver transplant rejection (corticosteroids and ATG) has remained unchanged for six decades, and is not infrequently met with treatment failure. Here,…
2022 American Transplant Congress
Cold Ischemia Time is More Critical for Older Donor Kidney Survival: A Machine Learning Approach
J. Kim, J. Ahn, A. Massie, D. Segev, S. Bae
Johns Hopkins, Baltimore, MD
*Purpose: Increasing utilization of kidneys from older donors is a potential solution to mitigate the organ shortage. However, older donor age is a risk factor…
2022 American Transplant Congress
Sirolimus Regimens After Kidney Transplantation: Role of Pre-Transplant Risk Factors in Modifying the Risk of Mortality in Adult Recipients
A. Santos¹, H. Ibrahim¹, M. A. Leghrouz¹, X. Wen²
¹University of Florida, Gainesville, FL, ²University of Rhode Island, Kinston, RI
*Purpose: We aimed to investigate the role of risk factors in modifying the association of sirolimus with mortality in kidney transplant (KT) recipients (KTRs).*Methods: Using…
2022 American Transplant Congress
Impact of Target Tacrolimus Levels on BK Polyomavirus DNAemia and Allograft Rejection Among Pediatric Kidney Transplant Recipients
H. Huang¹, P. Winterberg¹, R. George¹, A. Serluco², R. Liverman², I. Yildirim³, R. Garro¹
¹Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Yale University School of Medicine, New Haven, CT
*Purpose: BK Polyomavirus (BK) DNAemia is a serious and common infectious complication after kidney transplant (KT). We evaluated the impact of targeting lower tacrolimus levels…
2022 American Transplant Congress
Decellularized Human Pancreatic Extracellular Matrix-Based Physiomimetic Microenvironment for Human Islet Culture
A. Asthana¹, D. Chaimov¹, R. Tamburrini², S. J. Walker³, G. Orlando¹
¹Wake Forest Baptist Medical Center, Winston-Salem, NC, ²University of Wisconsin Hospital and Clinics, Madison, WI, ³Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC
*Purpose: Maintenance of human islet viability and function ex vivo can be a significant bottleneck for both regenerative medicine as well as tissue engineering applications.…
2022 American Transplant Congress
Stem Cell Donor-Derived CPRA Better Reflects Sensitization Than Current CPRA
K. Lindblad¹, C. Murphey², P. Lalli³, J. Lunz⁴, L. Gragert⁵
¹UNOS, Richmnd, VA, ²Southwest Immunodiagnostics, Inc., San Antonio, TX, ³Carolinas Medical Center, Charlotte, NC, ⁴LifeLink Foundation Transplant Immunology Lab, Tampa, FL, ⁵Tulane University School of Medicine, New Orleans, LA
*Purpose: The OPTN Histocompatibility Committee proposes replacing the current calculated panel reactive antibody (CPRA), based on HLA haplotype frequencies from ~14,000 deceased kidney donors, with…